Medical Conditions

Browse by Category

Multiple Sclerosis

MS Drug Restricted in Europe

MS Drug Restricted in Europe

Multiple sclerosis drug Lemtrada has been found to have serious — even fatal — side effects which have led the European Medicines Agency (EMA) to temporarily restrict the drug’s use while an official review is ongoing. Lemtrada has been approved in the US for the treatment of MS since 2014….

FDA Warns About Stroke, Artery Tear Risk With Multiple Sclerosis Drug

FDA Warns About Stroke, Artery Tear Risk With Multiple Sclerosis Drug

The FDA is warning that it has received a small number of serious reports of stroke and tears in the lining of head and neck arteries in patients taking the multiple sclerosis (MS) drug Lemtrada (alemtuzumab). The agency has received reports of 14 such cases since Lemtrada was approved for…

MS Drug Pulled from Market Worldwide

MS Drug Pulled from Market Worldwide

A multiple sclerosis (MS) drug is being pulled from the market worldwide after reports of brain inflammation and severe liver damage. Due to safety concerns, Biogen and AbbVie announced that they will be voluntarily withdrawing the drug Zinbryta (daclizumab), an biologic administered once a month to treat relapsing MS. This…

MS Drug May Boost Risk of Some Types of Cancer

MS Drug May Boost Risk of Some Types of Cancer

A drug used to treat multiple sclerosis (MS) has been linked to an increased risk of colorectal cancer and leukemia. People who were treated with Novantrone (mitoxantrone), had colorectal cancer rates that were 3x higher than the general population, according to an analysis by German researchers. Even more disturbing, the…

New MS Drug Fails Risk vs. Benefit Analysis

New MS Drug Fails Risk vs. Benefit Analysis

Lemtrada is a proposed new drug for the treatment of relapsing Multiple Sclerosis (MS). It is injected once a year (over the course of 5 days the first year, 3 days subsequent years). It has already been accepted in the European Union, Canada and Australia. However, the FDA has taken…

  • Advertisement